Atlas Trials

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT03361306 · COMPLETED

Trial details

NCT number
NCT03361306
Sponsor
Wake Forest University Health Sciences
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2018-01-09
Primary completion
2021-06-04
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.